Neuland Laboratories Ltd. News and Updates

Name: Latest research reports of Neuland Laboratories Ltd. authored by HDFC Securities and published by - Trendlyne research reports.
Item: Neuland Laboratories Ltd.
Rating: 5
Author: HDFC Securities

Keep track of all breaking news on Neuland Laboratories Ltd. from all sources in a single place.

Load latest

Neuland Laboratories Ltd.

14 Feb 2019

13083.00

0.51%

Neuland Labs (3QFY19): Recovery in sight. Maintain BUY

Buy: Neuland Laboratories Ltd.

Target

HDFC Securities

Remain bullish on the stock and maintain BUY with a TP of Rs 830 (14x Dec-20E EPS). Neuland Labs (NLL) reported encouraging numbers with 41% YoY revenue growth and a 73% YoY jump in EBITDA in 3QFY19. However, EBITDA margin remained muted at 9% of sales (in line) on account of continued raw material pressure, underutilized facilities and inferior business mix. PAT at Rs 46mn was up 5x YoY.

Number of FII/FPI investors increased from 250 to 259 in Jun 2025 qtr.

Neuland Laboratories Ltd.

29 Nov 2018

13083.00

0.51%

Neuland Laboratories receives US FDA approval

Business Line

Neuland Laboratories on Thursday informed the exchanges that the United States Food and Drug Administration inspected one of its manufacturing facilit

Neuland Laboratories Ltd. is trading below its 200 day SMA of 13188.6

Neuland Laboratories Ltd.

12 Aug 2018

13083.00

0.51%

Neuland Labs (1QFY19): Difficult times. Maintain BUY

Buy: Neuland Laboratories Ltd.

Target

HDFC Securities

Maintain BUY with a TP of Rs 914 (16x FY20E EPS) Neuland Labs (NLL) delivered poor performance in its 1QFY19 results. Revenue grew 31%YoY to Rs 1.54bn (down 4%QoQ) and EBITDA at Rs 90mn was up 11.3%YoY (sequential drop of 52%) with margin at 5.8% (declining by ~100bpsYoY). PAT reduced by 37%YoY and 95%QoQ, standing at Rs 4.1mn.

Neuland Laboratories Ltd. is trading below its 200 day SMA of 13188.6

Neuland Laboratories Ltd.

12 May 2018

13083.00

0.51%

Neuland Labs (4QFY18): Getting it right. Maintain BUY

Buy: Neuland Laboratories Ltd.

Target

HDFC Securities

Re-iterate BUY with a TP of Rs 1,000 (16x on FY20E EPS). Ahead of expectations, Neuland Labs (NLL) ended the year with improved business performance. Top line grew 13.2% YoY/31.5% QoQ to Rs 1.6bn, with significant jump seen in Ciprofloxacin and Levetiracetam revenues during this quarter. EBITDA declined 34%YoY to Rs 188mn. However, sequential growth of 105% was encouraging. EBITDA margin stood at 11.7% (down 838bps YoY, up 420bps QoQ and 170bps ahead of expectation). Reported PAT after merging with NHSPL and NPRPL, came in at Rs 81mn in 4QFY18.

Neuland Laboratories Ltd. is trading above its 150 day SMA of 12571.4

Neuland Laboratories Ltd.

09 Apr 2018

13083.00

0.51%

Neuland Labs: Board approves QIP issue

Business Line

The board of Neuland Laboratories on Monday approved a qualified placement issue. The company will issue up to 16.75 lakh shares through QIP. The proc

Neuland Laboratories Ltd. is trading above its 150 day SMA of 12571.4

Neuland Laboratories Ltd.

15 Mar 2018

13083.00

0.51%

Neuland Labs (Initiating Coverage): Neu' growth avenues. BUY

Buy: Neuland Laboratories Ltd.

HDFC Securities

Initiate coverage with a BUY rating and target price of Rs 1,065 (16x FY20E). Although NCE drug research remains a distant dream for Indian pharma companies, they are making strong inroads into API CRAMS which is at the core of innovation for pharma MNCs. Neuland Labs (NLL) is one among these Indian companies. NLL has made great strides in API CRAMS over the past few years and has managed to win clients from key regulated markets like the US, Europe and Japan.

Neuland Laboratories Ltd. is trading below its 200 day SMA of 13188.6

Neuland Laboratories Ltd.

08 Apr 2017

13083.00

0.51%

Neuland Labs gets 2 USFDA observations for Hyderabad facility

Business Line

The US Food and Drug Administration (USFDA) has made two observations on the manufacturing facility of Neuland Laboratories here. The US regulator had inspected Neuland's Unit 1 at Bonthapally,...

Neuland Laboratories Ltd. is trading below its 200 day SMA of 13188.6

Neuland Laboratories Ltd.

09 Nov 2016

13083.00

0.51%

Neuland Laboratories Ltd Q2FY17 Result Review

Buy: Neuland Laboratories Ltd.

BOB Capital Markets Ltd.

Amalgamation Scheme: The scheme involves issue of fresh equity shares by NLL to NHSPL and NPRPL which would increase NLL's equity by 25.6%. Promoter holding would change from 51.68% to 41.29 % post-merger. This would likely come into effect from Q2FY18. The amalgamation is aimed at building stronger business and financials, obtain tax benefits by clubbing R&D; services required for CMS business & better operational convenience. Going forward, we expect NLL to enjoy high margins led by strong...

Neuland Laboratories Ltd. is trading below its 200 day SMA of 13188.6

Neuland Laboratories Ltd.

05 Oct 2016

13083.00

0.51%

InvAscent in talks to exit Neuland Group

livemint

InvAscent, which holds 33% stake in Neuland Group, has hired the investment banking arm of IDFC Bank to advise on the stake sale

Neuland Laboratories Ltd. is trading below its 200 day SMA of 13188.6

Neuland Laboratories Ltd.

30 Sep 2016

13083.00

0.51%

Neuland Laboratories Ltd Initiating coverage with BUY

Buy: Neuland Laboratories Ltd.

BOB Capital Markets Ltd.

Strengthening High-Margin Product Portfolio: Being a pure generic API Player, NLL is shifting its focus to high margin products like Niche molecules and CMS. Revenue from Niche Molecule/CMS has grown at a CAGR of 28%/28% over FY14-FY16 and is expected to grow at a CAGR of 17%/38% over FY16-19e. As a result of this strong business mix, the EBITDA has grown at a CAGR of 6.7% over FY14-16 and going ahead the growth expected to be at a CAGR of ~25% over FY16-19e. The EBITDA...

Number of FII/FPI investors increased from 250 to 259 in Jun 2025 qtr.

Is Neuland Laboratories Ltd. worth buying?

178 Votes:

Buy 76.97%

Sell 14.04%

Hold 8.99%

27.72% Fall from 52W High

Neuland Laboratories Ltd. News and Updates

Keep track of all breaking news on Neuland Laboratories Ltd. from all sources in a single place.